Share Buyback & Completion of Buyback Programme

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Share Buyback

& Completion of Share Buyback Programme

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 159,000 of its ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a weighted average price of 25.6875 pence per share. The Ordinary Shares purchased will be held in treasury.

This transaction marks the successful conclusion of the share buyback programme announced on 21 May 2025 and the subsequent extension as set out in the announcement on 21 October 2025. Pursuant to the share buyback programme, a total of 17,130,678 ordinary shares were purchased at a weighted average cost of 26.14 pence per Ordinary Share.

Aggregated information

 Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:

Total voting rights

Following the purchase, the Company's total issued share capital will consist of 435,383,092 Ordinary Shares, of which 3,419,980 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 431,963,112. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

PDMR dealing

As part of the buyback and within the above aggregate purchase, EKF acquired 47,000 Ordinary Shares in total at a price of 25.6875 pence per Ordinary Share from Harwood as investment manager to Oryx International Growth Fund Limited ("Oryx") and North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"). EKF acquired 15,667 and 31,333 Ordinary Shares from Oryx and NASCIT respectively. Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.

Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company, Mr. Mills' aggregate indirect interest in the Company is 127,381,000 Ordinary Shares. 

Additional disclosures relating to this PDMR dealing are detailed below.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). 

The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them